CD274 and melanoma: The risk of discontinuing anti-PD-1 therapy has also been reported in previous studies, such as in advanced melanoma patients with PR or SD who had a higher risk of disease progression after discontinuation than patients with CR [47], possibly due to discontinuation of PD-1/PD-L1 inhibition.